Psychopharmacology 107

Clozapine levels are most affected by which of the following factors?


Smoking can have a significant effect on clozapine levels.

Clozapine (levels)


The average clozapine dose in the UK is 450 mg/day.

A 'therapeutic range' has not been established. It is generally accepted that a level of 350 µg/L is necessary to achieve a therapeutic response. Levels greater than 500 µg/L should be treated with caution as there is a risk of seizures.

Lower doses may be required in non-smokers, the elderly, females, and in patients using enzyme inhibitors (e.g. SSRI's).

Treatment should of course be guided by clinical response (treat the patient not the level).

Plasma levelAction
<350 µg/LIf response good then no action. 

If response poor increase dose to get a level of 350 µg/L
350 - 500 µg/LIf response good then no action

If response poor then increase dose to get level >500 µg/L and consider prophylactic anticonvulsant when dose get beyond 500µg/L
500 - 1000 µg/LIf response good then try to reduce dose to within 350 - 500 µg/L. If patient can't tolerate lower dose then consider prophylactic anticonvulsant.

If poor response then consider prophylactic anticonvulsant and consider augmentation
>1000 µg/LIf response good then add anticonvulsant. If well tolerated then continue, if not then attempt dose reduction to get level of <1000 µg/L. 

If response poor then add anticonvulsant and attempt augmentation. Consider abandoning clozapine

Above table adapted from Maudsley Guidelines 12th Edition.

Psychopharmacology 106

Which one of the following features is least recognised in long-term lithium use?


Lithium (side-effects)


Side-effects of lithium include:-

  • Drowsiness
  • Dry mouth
  • Polyuria
  • Polydipsia
  • Nausea
  • Weight gain
  • Fine tremor
  • Metallic taste
  • Diarrhoea
  • Muscle weakness

Side-effects are dose (plasma level) related. Propranolol can be helpful for fine tremor. Lithium is also known to exacerbate certain skin conditions including psoriasis and acne.

Long-term use is associated with the following:-

  • Hypothyroidism
  • Irreversible nephrogenic diabetes insipidus
  • Reduced GFR (chronic kidney disease)
  • Hyperparathyroidism

Psychopharmacology 105

Which of the following drugs acts by interacting with a G-coupled receptor?


Heroin acts by binding to opiate receptors. Opiate receptors are G-coupled and stimulation leads to inhibition of cellular activity.

Illicit drugs (mechanism of action)


Illicit drugs can be classified according to their mechanism of action.

MechanismExamples
Drugs which interfere with ionotropic receptors or ion channelsAlcohol, nicotine, benzodiazepines, ketamine
Drugs which interfere with G coupled receptorsOpioids, cannabinoids, y-hydroxybutyrate (GHB)
Drugs that target monoamine transportersAmphetamine, ecstasy, cocaine

The mechanistic classification of addictive drugs. PLoS Medicine, 3: e437.

The main mechanism by which cocaine and amphetamine act is by increasing levels of dopamine in the synaptic cleft. They do this however in slightly different ways.

Cocaine directly blocks the dopamine transporter (Massaro 2002), meaning that dopamine cannot be pumped back into the cell. This results in increased levels of dopamine in the synaptic cleft.

Amphetamine acts via two separate ways (Saunders et al 2000). Firstly it causes the dopamine transporter to internalise (leave the plasma membrane). This lack of dopamine transporters leads to a build up of dopamine in the synaptic cleft. Amphetamine also causes the presynaptic cytoplasmic vesicles to release their dopamine stores and so directly causes an increase of dopamine into the synaptic cleft.

Massaro J. Handbook of Neurotoxicology Volume 2 Humana Press, 2002.

Saunders et al. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. PNAS June 6, 2000

Psychopharmacology 104

According to NICE, which of the following is most appropriate first-line medication for treatment of insomnia which of less than 4 weeks duration?


Insomnia (treatments)


The NICE (2015) Clinical Knowledge Summary provides a useful guide on the management of insomnia. It splits the management into that of short-term insomnia (<4 weeks) and long-term insomnia (>4 weeks).

Short-term insomnia:

Consider a short course of a hypnotic drug only if daytime impairment is severe.

The hypnotics recommended for the treatment of insomnia are:

  • Short-acting benzodiazepines temazepam, loprazolam, lormetazepam.
  • Non-benzodiazepines (the 'z-drugs') zopiclone, zolpidem, and zaleplon (all are short acting).
  • Diazepam is not generally recommended, but it can be useful if insomnia is associated with daytime anxiety

If a hypnotic is prescribed:

  • Use the lowest effective dose for the shortest period possible. The exact duration will depend on the underlying cause, but treatment should not continue for longer than 2 weeks.
  • Inform the person that further prescriptions for hypnotics will not usually be given, ensure that the reasons for this are understood, and document this in the person's notes.
  • Do not issue further prescriptions without seeing the person again.
  • If there has been no response to the first hypnotic, do not prescribe another.
  • If the person experiences adverse effects considered to be directly related to an hypnotic, consider switching to another hypnotic.

Long-term insomnia

Refer to psychological services for a cognitive or behavioural intervention.

Pharmacological therapy is generally not recommended for the long-term management of insomnia but may be considered for immediate relief of symptoms.

If prescribing medication, use the lowest effective dose for the shortest period possible. The exact duration will depend on the underlying cause but should not continue for longer than 2 weeks. Up to 4 weeks' use may occasionally be required, but continued use should always be re-assessed after 2 weeks.

For people over 55 years of age with persistent insomnia, consider treatment with a modified-release melatonin. The recommended initial duration of treatment is 3 weeks. If there is a response to treatment, it can be continued for a further 10 weeks.

Additional detail from NICE regarding evidence base:

There is insufficient evidence to assess the effectiveness of sleep hygiene as a single intervention; however its use is widely supported by expert opinion in current literature and guidelines. 

There is good evidence for the efficacy of hypnotic drugs in short-term insomnia; however, their use is associated with adverse effects.

Tolerance to the hypnotic effects of benzodiazepine may be rapid, and may occur within a few days or weeks of regular use.

Dependence is more likely to develop with long-term use, high doses, more potent or shorter-acting benzodiazepines, and a history of anxiety problems. 

Diazepam, nitrazepam, and flurazepam are not recommended because their long half-life commonly gives rise to next-day residual effects, and repeated doses tend to be cumulative.

Sedative drugs other than hypnotics (such as antidepressants, antihistamines, choral hydrate, clomethiazole, and barbiturates) are not recommended for the management of insomnia. Expert opinion from reviews suggests that there is insufficient evidence to support their use, and that the potential for adverse effects is significant.

Modified-release melatonin (Circadin®) is only licensed for the management of primary insomnia (usually defined as more than 4 weeks' duration), and has only been studied in people with long-term insomnia.

The evidence on the efficacy of acupuncture is generally of poor methodological quality with inconsistent results. There is some evidence from single studies in a Cochrane systematic review to suggest that acupuncture and its variants (acupressure and transcutaneous electrical stimulation) may improve quality of sleep. Results for other sleep variables were inconsistent.

There is insufficient good quality evidence to make a recommendation regarding the efficacy of valerian, or any other herbal remedies, in the management of insomnia.

Good sleep hygiene includes:

  • Establish fixed times for going to bed and waking up (and avoid sleeping in after a poor night's sleep).
  • Try to relax before going to bed.
  • Maintain a comfortable sleeping environment: not too hot, cold, noisy, or bright.
  • Avoid napping during the day.
  • Avoid caffeine, nicotine, and alcohol within 6 hours of going to bed. (Consider complete elimination of caffeine from the diet.)
  • Avoid exercise within 4 hours of bedtime (although exercise earlier in the day is beneficial).
  • Avoid eating a heavy meal late at night.
  • Avoid watching or checking the clock throughout the night.
  • Only use the bedroom for sleep and sexual activity.

Psychopharmacology 103

Which of the following is a glutamate receptor regulator?


Exam Question Oct 2012

Mechanism of action


It is important to know the mechanisms of action of the different drugs. These are common questions in the exam, and easy marks if you make an effort to learn them.

AntidepressantMechanism
MirtazapineNoradrenaline and serotonin specific antidepressant (NaSSa)
5HT2 antagonist, 5HT3 antagonist, H1 antagonist, alpha 1 and alpha 2 antagonist, moderate muscarinic antagonist
VenlafaxineSerotonin and noradrenaline reuptake inhibitor (SNRI)
DuloxetineSerotonin and noradrenaline reuptake inhibitor (SNRI)
ReboxetineNoradrenaline reuptake inhibitor (NaRI)
St John's WortWeak MAOI and weak SNRI (also considered by some to be a weak SSRI)
TrazodoneWeak antagonist and SARI (Serotonin antagonist and reuptake inhibitor)
MoclobemideReversible inhibitor of monoamine oxidase type A
AgomelatineMelatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist
Bupropion (Zyban)Norepinephrine-dopamine reuptake inhibitor (NDRI), and nicotinic acetylcholine receptor antagonist

Antidementia drugMechanism
DonepezilReversible acetylcholinesterase inhibitor
RivastigmineReversible acetylcholinesterase inhibitor and butyrylcholinesterase inhibitor
GalantamineReversible acetylcholinesterase inhibitor and binds allosterically to the nicotinic acetylcholine receptor
TacrineReversible acetylcholinesterase inhibitor
MemantineNMDA antagonist

Mood stabiliserMechanism
ValproateGABA agonist and NMDA antagonist
GabapentinGABA agonist
TopiramateGABA agonist, NMDA antagonist, and Na channel stabiliser
CarbamazepineStabilises Na channels
PhenytoinStabilises Na channels
LamotrigineNMDA antagonist and stabilises Na channels
PregabalinPotent ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system

Anxiolytic/hypnotic drugMechanism
BenzodiazepinesGABA-A agonists
Z-drugsGABA-A agonists
Buspirone5HT1A partial agonist

AntipsychoticMechanism
AmisulprideD2/D3 selective antagonist (low affinity selective antagonist of 'D2 like' receptors (D2=D3>D4) it has little affinity for D1 like' receptors (D1 and D5) or non dopaminergic receptors (serotonin, histamine, adrenergic, and cholinergic)
OlanzapineDopamine and 5HT2 antagonism
AripiprazolePartial agonist at 5HT1A and D2, and 5HT2A antagonist
ClozapineHigh affinity for D4, (to a lesser extent D1, D2, D3, D5) also 5 HT 1A partial agonist and 5HT2 antagonist

Drug of abuseMechanism
KetamineNMDA antagonist
PhencyclidineNMDA antagonist

Other drugMechanism
LofexedineAlpha 2 agonist
ClonidineAlpha 2 agonist
BuprenorphinePartial agonist at the mu-opioid receptor
NaloxonePure opioid antagonist (will reverse mu, delta, and kappa)
AtomoxetineNoradrenaline reuptake inhibitor
Varenicline (Champix)Nicotinic receptor partial agonist
DisulfiramBinds irreversibly to aldehyde dehydrogenase
AcamprosateMetabotropic glutamate receptor antagonist and GABA-A agonist
Selegilineselective, irreversible inhibition of monoamine oxidase type B (also inhibits MAO-A at higher doses
SildenafilInhibits cGMP-specific phosphodiesterase type 5 (PDE5)

Psychopharmacology 102

Which of the following is most supportive of a diagnosis of mania?


Mania (features)


Features of mania include:-

  • Elated/ irritable mood
  • Restlessness and overactivity
  • Disinhibited behaviour
  • Reckless behaviour (e.g. Excessive spending)
  • Over ambitious plans for the future
  • Flight of ideas and pressured speech
  • Mood congruent delusion
  • Increased libido
  • Decreased need for sleep

Psychopharmacology 101

Which of the following drugs of abuse is detectable in the urine for the longest amount of time?


Drug (screening)


Note that detection times vary considerably from person to person. That being said the following table serves as a rough guide. As a general rule most substances remain positive in the urine for 1-3 days with the exception of heavy users of cannabis who can remain positive for up to 14-28 days.

Drug of abuseLength of time detectable in urine
Cannabis (heavy use)14-28 days
Cannabis (single use)3 days
Phencyclidine8 days
Methadone3 days
Morphine3 days
Benzodiazepine3 days
Heroin3 days
Cocaine1-3 days
Amphetamine1-3 days
LSD1-3 days
Codeine2 days
Alcohol12 hours

(Adapted from Synopsis of Psychiatry, Kaplan & Sadock's)

Standard drugs included in a urinalysis screen include:-

  • Cannabis
  • Amphetamine
  • Cocaine
  • Methadone
  • Benzodiazepines
  • Opiates